G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses

- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other...

Related Keywords

Japan ,China ,Jupiter Bioventures ,David Buttaro ,Jack Bailey ,Genor Biopharma ,Nathaniel David ,Gain Exclusive Rights For The Clinical Development ,Research Triangle Park ,Exchange Commission ,Nasdaq ,Linkedin ,Therapeutics Inc ,National Medical Products Administration ,Corporate Communications ,Gain Exclusive Rights ,Clinical Development ,Regulatory Submissions ,Deimos Biosciences ,Managing Director ,Pepper Bio ,Deimos Bioscience ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Bioventures Contact ,Investor Relations ,